Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 3c, Revenues Beat

August 8, 2019 6:55 AM

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.86, $0.03 better than the analyst estimate of $0.83. Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found